Anixa Biosciences Inc (NASDAQ:ANIX) Receives $8.50 Consensus Target Price from Analysts

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $8.50.

ANIX has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. HC Wainwright reaffirmed a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Zacks Research upgraded shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar purchased 21,000 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the acquisition, the chief executive officer directly owned 630,812 shares in the company, valued at approximately $1,577,030. The trade was a 3.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders purchased 50,024 shares of company stock valued at $148,971. Corporate insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC purchased a new stake in shares of Anixa Biosciences in the second quarter valued at about $33,000. Simplicity Wealth LLC purchased a new position in Anixa Biosciences during the second quarter worth $34,000. Cetera Investment Advisers purchased a new position in Anixa Biosciences during the fourth quarter worth $35,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences in the second quarter worth $37,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Stock Down 0.3%

NASDAQ ANIX opened at $3.42 on Friday. The stock has a market capitalization of $116.35 million, a P/E ratio of -11.03 and a beta of 0.55. Anixa Biosciences has a 52-week low of $2.32 and a 52-week high of $5.46. The firm has a 50-day moving average price of $3.04 and a 200 day moving average price of $2.93.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. On average, equities research analysts expect that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.